Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Summary

GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.

Timeline

Start

2012-11

Primary completion

2014-04

Completion

2014-06

Drugs

Indications